Market Share of 14% Achieved in the U.S. Cosmetic Toxin Market
Since becoming the first Asian company to receive FDA approval for its botulinum toxin in 2019, Daewoong Pharmaceutical has shown significant growth in the global market. The United States, in particular, is the largest market for botulinum toxin worldwide and is known for having the strictest standards for quality, safety, and manufacturing control. Daewoong Pharmaceutical is strengthening its premium strategy, which emphasizes high purity and high quality, by expanding educational and academic programs for medical professionals.
Nabota has achieved solid results across global markets. In the U.S. cosmetic toxin market, it is sold under the brand name Jeuveau and has achieved a 14% market share, ranking second in the market.
Growth has also been notable in South America and Southeast Asia. In Brazil, Daewoong Pharmaceutical signed an export contract worth 180 billion KRW, which is ten times larger than its first contract in 2018. In Thailand, the company renewed its export agreement to a scale of 73.8 billion KRW, three times larger than the previous contract.
Daewoong Pharmaceutical recently signed an export contract with Kuwait, enabling Nabota to be supplied to five countries in the Middle East?a record for a Korean toxin company. Among the six Gulf countries with high demand for premium cosmetic and plastic surgery procedures, Daewoong Pharmaceutical has rapidly expanded its presence in four: the UAE, Saudi Arabia, Qatar, and Kuwait.
In the second half of the year, the company plans to build on its first-half performance by further increasing its market share in existing countries and actively pursuing entry into new markets.
Through its proprietary Nabota Lift technique and combined procedure training programs, Nabota is establishing itself as a leader in the "K-Medical Aesthetic" trend. Daewoong Pharmaceutical aims to go beyond simple marketing by genuinely enhancing the procedural capabilities of local medical professionals, improving patient satisfaction and service quality, and ultimately creating a win-win-win model that benefits the company, medical professionals, and patients alike.
Daewoong Pharmaceutical continues to conduct global academic activities such as conferences, webinars, and training programs on various combined procedures, including Nabota Lift. The company is also expanding clinical research collaborations with local medical professionals, further strengthening the scientific evidence for Nabota's superior quality and safety.
Yoon Joonsoo, Head of the Nabota Business Division at Daewoong Pharmaceutical, stated, "Nabota has now firmly established itself as a global top-tier brand leading trends in the global market. With our premium product strength, defined by high purity and high quality, we will further solidify our competitiveness in major markets worldwide and advance as a leader in the global medical aesthetics market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
